scPharmaceuticals

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

scPharmaceuticals reports Q4 loss, sees growth potential with FUROSCIX

scPharmaceuticals' financials show investment in the FUROSCIX launch, with a net loss reported for Q4 2022 and the full year.
FUROSCIX's commercial success, distribution partnerships, and evolving physician perceptions are key strengths for the company.
Challenges lie in reimbursement processes, achieving target co-pays, and aligning on optimal FUROSCIX use timing among doctors.
Opportunities include the substantial market potential, targeted outreach to hospitals, and driving prescriptions through in-services.

scPharmaceuticals reports mixed Q1 results, FUROSCIX shows promising market reception

scPharmaceuticals reported mixed financials with strong revenue but a net loss in Q1 2023.
FUROSCIX's success in the market and positive feedback position it well for future growth.
Challenges exist in managing expenses and securing broader coverage for the treatment.
Opportunities lie in expanding patient access, improving authorization rates, and driving revenue growth.

scPharmaceuticals reports $1.6M Q2 revenue, eyes FDA filing expansion

scPharmaceuticals (SCPH) reported mixed financial results for Q2, with strong revenue but a net loss. The company is focused on expanding FUROSCIX's market reach, improving gross to net discount, and enhancing brand awareness through marketing efforts. Anticipated FDA filing and plans for indication expansion signal growth potential.

scPharmaceuticals reports stellar Q3 performance, eyes market expansion opportunities

scPharmaceuticals delivered robust financial results in Q3 2023, driven by strong revenue growth and improved gross profit margins.
Strategic initiatives to expand market reach and access to FUROSCIX position the company for sustained growth and market penetration.
While facing challenges in pricing dynamics and regulatory expansions, scPharmaceuticals holds significant opportunities for growth and value creation.

scPharmaceuticals reports strong Q4 earnings and eyes market expansion

scPharmaceuticals showcased robust financial performance and strategic growth initiatives in Q4 2023, driven by FUROSCIX sales.
While facing market complexities and operational challenges, the company maintains a strong cash position and optimistic outlook for future initiatives.
Opportunities lie in market access negotiations, streamlined regulatory processes, and expanding product coverage, positioning scPharmaceuticals for continued success.

scPharmaceuticals reports Q1 challenges but remains optimistic for 2024

scPharmaceuticals faced challenges in Q1 due to a cyber attack and increased expenses, but showed resilience with positive trends in FUROSCIX utilization and growth initiatives. The company remains optimistic for continued momentum and life cycle initiatives in 2024.

scPharmaceuticals reports robust Q2 performance and regulatory wins

scPharmaceuticals delivered strong financial performance and regulatory milestones in Q2 2024, positioning the company for growth.
While facing operational challenges and competitive pressures, the company's strategic strengths and opportunities offer avenues for future success.
With a focus on innovation, market expansion, and financial stability, scPharmaceuticals is poised for continued growth and value creation.
Investors can be optimistic about scPharmaceuticals' progress and potential in the pharmaceutical market based on the Q2 performance and strategic initiatives.

scPharmaceuticals reports revenue growth and strategic advancements in Q3

scPharmaceuticals demonstrated revenue growth and strategic advancements in Q3 2024, underpinned by strong FUROSCIX sales and key initiatives.
While facing challenges such as ongoing losses and pricing dynamics, the company's focus on innovation and commercial progress positions it well for future growth.
With opportunities in seasonal demand, market expansion, and a solid financial base, scPharmaceuticals is poised for continued development and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide

scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX® (furosemide injection) at home Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX® (furosemide injection) at home

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

BURLINGTON, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced today that John Tucker, president & chief executive officer, is scheduled to present virtually at the H.C. Wainwright 24th Annual Global Investment Conference, which is being held in a hybrid format, in-person and virtually, from September 12-14 in New York.

scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022

scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

BURLINGTON, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced today that John Tucker, president & chief executive officer, is scheduled to participate in the Late-Stage Advancements in Heart Failure Therapeutics and Management panel discussion, presented by Maxim Group LLC and hosted by M-Vest, on Thursday, July 14th, 2022 at 10:00 a.m. ET.

scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion

Study results favor FUROSCIX ® versus “treatment as usual” in composite primary endpoint and all secondary endpoints

scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure

Virtual event scheduled for Wednesday, July 13 at 10:00 AM EDT Virtual event scheduled for Wednesday, July 13 at 10:00 AM EDT

scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients

Oral and moderated poster presentations of FREEDOM-HF study to be presented Oral and moderated poster presentations of FREEDOM-HF study to be presented

scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting

BURLINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24 at 3:00pm EDT, at the Fontainebleau Miami Beach Hotel in Miami, FL.

scPharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

FDA assigns PDUFA action date of October 8, 2022

scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

PDUFA action date set for October 8, 2022

scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX® New Drug Application

Anticipates Q4 2022 commercial launch, if approved Anticipates Q4 2022 commercial launch, if approved

scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application

Successfully completed all testing; plan to re-submit FUROSCIX® NDA by April 15, 2022

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

BURLINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 42nd Annual Cowen Healthcare Conference on Tuesday, March 8 at 1:30pm EST.

scPharmaceuticals to Present at the 42nd Annual Cowen Healthcare Conference

BURLINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 4:20pm EDT.

scPharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference

All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date

scPharmaceuticals Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

BURLINGTON, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies London Healthcare Conference, which is being held in-person on November 16-17 and virtually November 18-19.

scPharmaceuticals to Present at the Jefferies London Healthcare Conference

Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group

scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

The FUROSCIX NDA resubmission is expected to occur during 4Q21.

scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX

Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX® NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4

scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

scPharmaceuticals Inc (NASDAQ: SCPH) announced top-line results from its FREEDOM-HF study evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure.  Patients were treated with the Company's investigational Furoscix, post-discharge from the emergency department, compared to a historical comparator group treated with intravenous furosemide in the inpatient hospital setting.

scPharma's Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients

Reduced average 30-day heart failure related costs by $17,753 (p

scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study

The stock price of scPharmaceuticals Inc (NASDAQ: SCPH) increased by over 18% during intraday trading. This is why it happened.

SCPH Stock Price Increases Over 18%: Why It Happened

BURLINGTON, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 EDT.

News for scPharmaceuticals Stock (SCPH)